<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "3: of the Company and the Company ", fill: "#967117"},
{source: "3: of the Company and the Company ", target: "3: cannot unilaterally", fill: "#967117"},
{source: "3: of the Company and the Company ", target: "4: pharmacies owed", fill: "#967117"},
{source: "4: pharmacies owed", target: "4: Company ", fill: "#967117"},
{source: "4: pharmacies owed", target: "12: shareholders", fill: "#614051"},
{source: "12: shareholders", target: "12: entered into", fill: "#614051"},
{source: "12: entered into", target: "12: stock exchange", fill: "#614051"},
{source: "12: stock exchange", target: "12: Agreement ", fill: "#614051"},
{source: "12: Agreement ", target: "12: reorganization", fill: "#614051"},
{source: "12: reorganization", target: "12: the Company ", fill: "#614051"},
{source: "12: the Company ", target: "12: by exchange with", fill: "#614051"},
{source: "12: by exchange with", target: "12: outstanding stock", fill: "#614051"},
{source: "12: outstanding stock", target: "12: five members two", fill: "#614051"},
{source: "12: five members two", target: "12: minority shareholders", fill: "#614051"},
{source: "12: minority shareholders", target: "12: Shareholders ", fill: "#614051"},
{source: "12: Shareholders ", target: "12: fifth director", fill: "#614051"},
{source: "12: fifth director", target: "12: affiliated with", fill: "#614051"},
{source: "12: affiliated with", target: "12: Shareholders or the Company", fill: "#614051"},
{source: "12: shareholders", target: "15: agreement also provides", fill: "#6ca0dc"},
{source: "15: agreement also provides", target: "15: operations", fill: "#6ca0dc"},
{source: "15: operations", target: "15: cash management", fill: "#6ca0dc"},
{source: "15: cash management", target: "15: managed by", fill: "#6ca0dc"},
{source: "15: managed by", target: "15: Shareholders", fill: "#6ca0dc"},
{source: "15: agreement also provides", target: "29: capital cannot", fill: "#87a96b"},
{source: "29: capital cannot", target: "29: the Company ", fill: "#87a96b"},
{source: "29: the Company ", target: "29: minority shareholders may enforce", fill: "#87a96b"},
{source: "29: capital cannot", target: "31: principally dependent upon", fill: "#00755e"},
{source: "31: principally dependent upon", target: "31: management team", fill: "#00755e"},
{source: "31: principally dependent upon", target: "32: distribution", fill: "#66023c"},
{source: "32: distribution", target: "32: subsidiaries", fill: "#66023c"},
{source: "32: subsidiaries", target: "32: services principally", fill: "#66023c"},
{source: "32: services principally", target: "32: supplying accounting services", fill: "#66023c"},
{source: "32: distribution", target: "40: Samuel Nyer ", fill: "#228b22"},
{source: "40: Samuel Nyer ", target: "40: common stock", fill: "#228b22"},
{source: "40: Samuel Nyer ", target: "67: professional liability", fill: "#b39eb5"},
{source: "67: professional liability", target: "67: omissions liability", fill: "#b39eb5"},
{source: "67: omissions liability", target: "67: insurance from", fill: "#b39eb5"},
{source: "67: insurance from", target: "67: significant", fill: "#b39eb5"},
{source: "67: significant", target: "67: funded by insurance", fill: "#b39eb5"},
{source: "67: professional liability", target: "73: health care industry", fill: "#f88379"},
{source: "73: health care industry", target: "73: government regulation", fill: "#f88379"},
{source: "73: health care industry", target: "75: Additionally Eaton ", fill: "#c32148"},
{source: "75: Additionally Eaton ", target: "75: Drug Enforcement Agency ", fill: "#c32148"},
{source: "75: Drug Enforcement Agency ", target: "75: regulations", fill: "#c32148"},
{source: "75: Additionally Eaton ", target: "88: one vendor whose", fill: "#007fff"},
{source: "88: one vendor whose", target: "88: relationship", fill: "#007fff"},
{source: "88: relationship", target: "88: accounts", fill: "#007fff"},
{source: "88: accounts", target: "88: inventory purchases", fill: "#007fff"},
{source: "88: one vendor whose", target: "120: SarbanesOxley Act ", fill: "#f400a1"},
{source: "120: SarbanesOxley Act ", target: "120: management", fill: "#f400a1"},
{source: "120: management", target: "120: independent", fill: "#f400a1"},
{source: "120: independent", target: "120: accounting", fill: "#f400a1"},
{source: "120: accounting", target: "120: effectiveness", fill: "#f400a1"},
{source: "120: SarbanesOxley Act ", target: "START_HERE", fill: "#f400a1"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Pharmaceuticals</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Health Care Supplies</td>
    </tr>
    <tr>
      <td>Health Care</td>
    </tr>
    <tr>
      <td>Health Care Equipment and Services</td>
    </tr>
    <tr>
      <td>Managed Health Care</td>
    </tr>
    <tr>
      <td>Oil and Gas Exploration and Production</td>
    </tr>
    <tr>
      <td>Human Resource and Employment Services</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Independent Power Producers and Energy Traders</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Material Aid</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Empathize</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Defy norms</td>
    </tr>
    <tr>
      <td>Seize</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Holding_company">Holding company</a></td>
      <td>A holding company is a company whose primary business is holding a controlling interest in the securities of other companies. A holding company usually does not produce goods or services itself.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Public_company">Public company</a></td>
      <td>A public company, publicly traded company, publicly held company, publicly listed company, or public limited company is a company whose ownership is organized via shares of stock which are intended to be freely traded on a stock exchange or in over-the-counter markets. A public (publicly traded) company can be listed on a stock exchange (listed company), which facilitates the trade of shares, or not (unlisted public company).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Shareholder">Shareholder</a></td>
      <td>A shareholder (in the United States often referred to as stockholder) of a corporation is an individual or legal entity (such as another corporation, a body politic, a trust or partnership) that is registered by the corporation as the legal owner of shares of the share capital of a public or private corporation. Shareholders may be referred to as members of a corporation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Equity_(finance)">Equity (finance)</a></td>
      <td>In finance, equity is ownership of assets that may have debts or other liabilities attached to them. Equity is measured for accounting purposes by subtracting liabilities from the value of the assets.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Shareholder_loan">Shareholder loan</a></td>
      <td>Shareholder loan is a debt-like form of financing provided by shareholders. Usually, it is the most junior debt in the company's debt portfolio.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Berkshire_Hathaway">Berkshire Hathaway</a></td>
      <td>Berkshire Hathaway Inc. () is an American multinational conglomerate holding company headquartered in Omaha, Nebraska, United States.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Annual_general_meeting">Annual general meeting</a></td>
      <td>An annual general meeting (AGM, also known as the annual meeting) is a meeting of the general membership of an organization.\nThese organizations include membership associations and companies with shareholders.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Treasury_stock">Treasury stock</a></td>
      <td>A treasury stock or reacquired stock is stock which is bought back by the issuing company, reducing the amount of outstanding stock on the open market ("open market" including insiders' holdings). \nStock repurchases are used as a tax efficient method to put cash into shareholders' hands, rather than paying dividends, in jurisdictions that treat capital gains more favorably.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_Activities_Center">Special Activities Center</a></td>
      <td>The Special Activities Center (SAC) is a division of the Central Intelligence Agency responsible for covert operations and paramilitary operations. The unit was named Special Activities Division (SAD) prior to 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Management_accounting">Management accounting</a></td>
      <td>In management accounting or managerial accounting, managers use accounting information in decision-making and to assist in the management and performance of their control functions.\n\n\n== Definition ==\n\nOne simple definition of management accounting is the provision of financial and non-financial decision-making information to managers.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Governmental_accounting">Governmental accounting</a></td>
      <td>Government accounting refers to the process of recording and the management of all financial transactions incurred by the government which includes its income and expenditures.\nVarious governmental accounting systems are used by various public sector entities.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Common_stock">Common stock</a></td>
      <td>Common stock is a form of corporate equity ownership, a type of security. The terms voting share and ordinary share are also used frequently outside of the United States.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Common_stock_dividend">Common stock dividend</a></td>
      <td>A common stock dividend is the dividend paid to common stock owners from the profits of the company.  Like other dividends, the payout is in the form of either cash or stock.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Matthiola_incana">Matthiola incana</a></td>
      <td>Matthiola incana is a species of flowering plant in the cabbage family Brassicaceae. Common names include Brompton stock, common stock, hoary stock, ten-week stock, and gilly-flower.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Consolidation_(business)">Consolidation (business)</a></td>
      <td>In business, consolidation or amalgamation is the merger and acquisition of many smaller companies into a few much larger ones. In the context of financial accounting, consolidation refers to the aggregation of financial statements of a group company as consolidated financial statements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Convertible_bond">Convertible bond</a></td>
      <td>In finance, a convertible bond or  convertible note or convertible debt (or a convertible debenture if it has a maturity of greater than 10 years) is a type of bond that the holder can convert into a specified number of shares of common stock in the issuing company or cash of equal value.  It is a hybrid security with debt- and equity-like features.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_figures">Significant figures</a></td>
      <td>Significant figures (also known as the significant digits, precision or resolution) of a number in positional notation are digits in the number that are reliable and necessary to indicate the quantity of something.\nIf a number expressing the result of a measurement (e.g., length, pressure, volume, or mass) has more digits than the number of digits allowed by the measurement resolution, then only as many digits as allowed by the measurement resolution are reliable, and so only these can be significant figures.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_other">Significant other</a></td>
      <td>The term significant other (SO) has different uses in psychology and in colloquial language. Colloquially "significant other" is used as a gender-neutral term for a person's partner in an intimate relationship without disclosing or presuming anything about marital status, relationship status, gender identity, or sexual orientation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_form">Significant form</a></td>
      <td>Significant form refers to an aesthetic theory developed by English art critic Clive Bell which specified a set of criteria for what qualified as a work of art.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Statistical_significance">Statistical significance</a></td>
      <td>In statistical hypothesis testing, a result has statistical significance when it is very unlikely to have occurred given the null hypothesis. More precisely, a study's defined significance level, denoted by \n  \n    \n      \n        α\n      \n    \n    {\displaystyle \alpha }\n  , is the probability of the study rejecting the null hypothesis, given that the null hypothesis is true; and the p-value of a result, \n  \n    \n      \n        p\n      \n    \n    {\displaystyle p}\n  , is the probability of obtaining a result at least as extreme, given that the null hypothesis is true.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Simpsons">The Simpsons</a></td>
      <td>The Simpsons is an American animated sitcom created by Matt Groening for the Fox Broadcasting Company. The series is a satirical depiction of American life, epitomized by the Simpson family, which consists of Homer, Marge, Bart, Lisa, and Maggie.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_Mother">Significant Mother</a></td>
      <td>Significant Mother is an American television sitcom created by Erin Cardillo and Richard Keith. Starring Josh Zuckerman, Nathaniel Buzolic and Krista Allen, it premiered on The CW network on August 3 and ended its run on October 5, 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Internet">Internet</a></td>
      <td>In finance and economics, interest is payment from a borrower or deposit-taking financial institution to a lender or depositor of an amount above repayment of the principal sum (that is, the amount borrowed), at a particular rate. It is distinct from a fee which the borrower may pay the lender or some third party.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation">Regulation</a></td>
      <td>Regulation is the management of complex systems according to a set of rules and trends. In systems theory, these types of rules exist in various fields of biology and society, but the term has slightly different meanings according to context.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation_A">Regulation A</a></td>
      <td>In the United States under the Securities Act of 1933, any offer to sell securities must either be registered with the United States Securities and Exchange Commission (SEC) or meet certain qualifications to exempt it from such registration. Regulation A (or Reg A) contains rules providing exemptions from the registration requirements, allowing some companies to use equity crowdfunding to offer and sell their securities without having to register the securities with the SEC. Regulation A offerings are intended to make access to capital possible for small and medium-sized companies that could not otherwise bear the costs of a normal SEC registration and to allow nonaccredited investors to participate in the offering.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Formula_One_regulations">Formula One regulations</a></td>
      <td>The numerous Formula One regulations, made and enforced by the FIA and later the FISA, have changed dramatically since the first Formula One World Championship in 1950. This article covers the current state of F1 technical and sporting regulations, as well as the history of the technical regulations since 1950.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation_(European_Union)">Regulation (European Union)</a></td>
      <td>A regulation is a legal act of the European Union that becomes immediately enforceable as law in all member states simultaneously. Regulations can be distinguished from directives which, at least in principle, need to be transposed into national law.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation_of_therapeutic_goods">Regulation of therapeutic goods</a></td>
      <td>The regulation of therapeutic goods, defined as drugs and therapeutic devices, varies by jurisdiction. In some countries, such as the United States, they are regulated at the national level by a single agency.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulations.gov">Regulations.gov</a></td>
      <td>Regulations.gov is a U.S. Federal government web site that acts as an "Internet portal and document repository" that allows members of the public to participate in the rulemaking processes of some Federal government agencies.  \nThe site allows users to make public comments in response to notices of proposed rulemaking issued by participating agencies; such comments become part of the public record and may be displayed on the site.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Radio_regulation">Radio regulation</a></td>
      <td>Radio regulation refers to the regulation and licensing of radio in international law, by individual governments, and by municipalities.\n\n\n== International regulation ==\nThe International Telecommunication Union (ITU) is a specialized agency of the United Nations (UN) that is responsible for issues that concern information and communication technologies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Cost_accounting">Cost accounting</a></td>
      <td>Cost accounting is defined as "a systematic set of procedures for recording and reporting measurements of the cost of manufacturing goods and performing services in the aggregate and in detail. It includes methods for recognizing, classifying, allocating, aggregating and reporting such costs and comparing them with standard costs." (IMA)  Often considered a subset of managerial accounting, its end goal is to advise the management on how to optimize business practices and processes based on cost efficiency and capability.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_accounting">Financial accounting</a></td>
      <td>Financial accounting is the field of accounting concerned with the summary, analysis and reporting of financial transactions related to a business. This involves the preparation of financial statements available for public use.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Accounting_software">Accounting software</a></td>
      <td>Accounting software is a computer program that maintains account books on computers, including recording transactions and account balances. Depending on the purpose, the software can manage budgets, perform accounting tasks for multiple currencies, perform payroll and customer relationship management, and prepare financial reporting.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>NYER MEDICAL GROUP INC    Item 1A RISK FACTORS    Item lB UNRESOLVED STAFF COMMENTS    ITEM 1A Risk Factors    <font color="blue">The Company </font>Has A Limited Amount of Cash to Fund Operating Needs         We had approximately dlra1cmam130cmam000 in cash at <font color="blue">September </font>26, 2006, as compared  to dlra814cmam119 in cash at June 30, 2006</td>
    </tr>
    <tr>
      <td>The <font color="blue">cash balances</font> of <font color="blue">the Company </font>and  <font color="blue">subsidiaries</font> were as follows at <font color="blue">September </font>26, 2006: pharmacies - dlra1cmam097cmam900,  medical - dlra23cmam100 and <font color="blue">the Company </font>dlra9cmam000</td>
    </tr>
    <tr>
      <td>Because the pharmacies are not a  wholly-owned subsidiary <font color="blue">of <font color="blue">the Company </font>and <font color="blue">the Company </font></font>does not have operating  control, it <font color="blue">cannot unilaterally</font> cause the pharmacies to loan funds to the  Company should  <font color="blue">the Company </font>require a loan</td>
    </tr>
    <tr>
      <td>The <font color="blue">pharmacies owed</font> the <font color="blue">Company  </font>approximately dlra27cmam000</td>
    </tr>
    <tr>
      <td>This is being <font color="blue">repaid monthly</font></td>
    </tr>
    <tr>
      <td>In October 2004, the Companyapstas medical segment obtained a dlra300cmam000 line of  credit which is <font color="blue">collateralized by property</font> owned by the subsidiary and  <font color="blue">guaranteed by</font> the Company</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font><font color="blue">cannot draw on</font> the <font color="blue">line without</font>  <font color="blue">approval from</font> a committee of the board of <font color="blue">directors</font>, specifically established  for this purpose</td>
    </tr>
    <tr>
      <td>The <font color="blue">interest rate</font> for the line of credit is the Wall Street  Journal Prime Rate</td>
    </tr>
    <tr>
      <td><font color="blue">Repayment </font>of the line of credit would be in monthly  payments of interests only, with the principal being due at maturity, unless  renewed</td>
    </tr>
    <tr>
      <td>Restricted Assets and Uncertainties         In August of 1996, <font color="blue">the Company </font>and the <font color="blue">shareholders</font> of DAW <font color="blue">entered into</font>  a <font color="blue">stock exchange</font> <font color="blue">Agreement </font>and plan of <font color="blue">reorganization</font> whereby the <font color="blue">Company  </font>acquired <font color="blue">by exchange with</font> the sellers 80prca of the issued and <font color="blue">outstanding stock</font>  of  DAW  The Board of Directors of DAW is comprised of five members, two  from the minority <font color="blue">shareholders</font> ( &amp;quote <font color="blue"><font color="blue">Shareholders</font> </font>&amp;quote ) and two from <font color="blue">the Company </font>and a  <font color="blue">fifth director</font> not <font color="blue">affiliated with</font> the <font color="blue"><font color="blue">Shareholders</font> </font>or the Company</td>
    </tr>
    <tr>
      <td>As part of an associated <font color="blue">shareholders</font> &amp;apos  <font color="blue">agreement</font>, <font color="blue">the Company </font>and the  <font color="blue"><font color="blue">Shareholders</font> </font>will not vote any of their shares in favor of, or consent to any  merger of DAW with another entity or any sale of all or <font color="blue">substantially</font> all of  the assets of DAW unless 80prca of the DAWapstas Board of Directors vote in  favor of the <font color="blue">transaction</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">agreement</font> also provides for the <font color="blue">operations</font> of the subsidiary,  including <font color="blue">cash <font color="blue">management</font></font>, to be <font color="blue">managed by</font> the <font color="blue">Shareholders</font></td>
    </tr>
    <tr>
      <td>The <font color="blue"><font color="blue">Shareholders</font> </font>of DAW have <font color="blue">employment</font> <font color="blue">agreement</font>s which expired in  August 2006</td>
    </tr>
    <tr>
      <td>Since the <font color="blue">agreement</font>s expired, these employees had the right to  require <font color="blue">the Company </font>to purchase all or any portion of their shares of DAW         In August 2006, <font color="blue">the Company </font><font color="blue">entered into</font> an <font color="blue">Agreement </font>with the  <font color="blue"><font color="blue">Shareholders</font> </font>which stated/accomplished the following:         <font color="blue">The Company </font><font color="blue">acknowledges</font> that 100prca of the shares of the <font color="blue">subsidiaries</font> of  <font color="blue">the Company </font>( &amp;quote <font color="blue">Subsidiaries </font>&amp;quote ) held by each <font color="blue">Shareholder </font>(the  &amp;quote Put Shares &amp;quote ) have  <font color="blue">been offered</font> to <font color="blue">the Company </font>for purchase</td>
    </tr>
    <tr>
      <td>The <font color="blue"><font color="blue">Shareholders</font> </font>agree to <font color="blue">refrain from</font> requiring <font color="blue">the Company </font>to  <font color="blue">immediately</font> pay the <font color="blue">fair market value</font> of the Put Shares until the earlier of  (i) the closing of the <font color="blue">transaction</font>(s) among the Company, the <font color="blue"><font color="blue">Shareholders</font> </font>and  the <font color="blue">Subsidiaries </font><font color="blue">with respect</font> to the <font color="blue">potential purchase by</font> <font color="blue">the Company </font>of all  of the shares held by the <font color="blue"><font color="blue">Shareholders</font> </font>in the <font color="blue">Subsidiaries </font>(the  &amp;quote Purchase &amp;quote ),  which may be accomplished by payment in full of <font color="blue">immediately</font> available funds,  and (ii) July 15, 2007</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>agrees to pay dlra16cmam665 per month in total to the <font color="blue"><font color="blue">Shareholders</font> </font> from the first business day of August 2006 until the earlier of (i) the closing  of the Purchase, and (ii) <font color="blue">December </font>15, 2006; and - dlra33cmam335 per month from and  after <font color="blue">December </font>16, 2006 - until the closing of the Purchase</td>
    </tr>
    <tr>
      <td>DAW agrees to advance to <font color="blue">the Company </font>the amounts <font color="blue">necessary</font> to make the  monthly payments, which amounts will be repaid by <font color="blue">the Company </font>to DAW,  (<font color="blue">with interest at</font> the applicable federal rate) upon the earlier of (i) the  closing of the Purchase, and (ii) July 15, 2007</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>pledges 2dtta5prca of its holdings in DAW <font color="blue">as collateral</font> for  the <font color="blue">monies advanced</font> to <font color="blue">the Company </font>by DAW to make the monthly payments noted  above</td>
    </tr>
    <tr>
      <td>The parties to the Forbearance <font color="blue">Agreement </font>agreed that the <font color="blue">fair market value</font>  of all of the shares of the <font color="blue">Subsidiaries </font>held by the <font color="blue"><font color="blue">Shareholders</font> </font>is dlra4  million</td>
    </tr>
    <tr>
      <td>The <font color="blue">arbitration clause</font> of the Forbearance <font color="blue">Agreement </font>was deleted in its  entirety and <font color="blue">replaced with</font> a <font color="blue">provision agreeing</font> to <font color="blue">jurisdiction</font> and venue in  the  Business Litigation Session of the Superior Court for the Commonwealth of  <font color="blue">Massachusetts</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>and the <font color="blue"><font color="blue">Shareholders</font> </font>are <font color="blue">presently attempting</font> to negotiate  <font color="blue">employment</font> <font color="blue">agreement</font>s and/or a buy out agreeable to all parties</td>
    </tr>
    <tr>
      <td>There is no  assurance that <font color="blue">the Company </font>will be able to <font color="blue">successfully negotiate <font color="blue">employment</font></font>  <font color="blue">agreement</font>s and/or raise the capital <font color="blue">necessary</font> to buy out the <font color="blue">Shareholders</font></td>
    </tr>
    <tr>
      <td>Should an <font color="blue">agreement</font> not be reached and/or capital not be raised, the  Company will be <font color="blue">faced with</font> a number of <font color="blue">uncertainties</font>:  If an <font color="blue">agreement</font> has not  been finalized by July 15, 2007, the <font color="blue"><font color="blue">Shareholders</font> </font><font color="blue">could seek <font color="blue">employment</font></font>  elsewhere and this would, in the short run, leave no <font color="blue">management</font> team for the  pharmacies and cause <font color="blue">the Company </font>to have to assemble an entire new <font color="blue">management</font>  team</td>
    </tr>
    <tr>
      <td>Three of the <font color="blue">store leases</font> are expiring in <font color="blue">fiscal year</font> 2007, including the  largest and most profitable one, which is owned by the mother of DAWapstas  president</td>
    </tr>
    <tr>
      <td>If an <font color="blue">agreement</font> is not negotiated, this lease may not be renewed</td>
    </tr>
    <tr>
      <td>If <font color="blue">capital cannot</font> be raised before the required date for the Put Shares to  be purchased by the Company, then the DAW minority <font color="blue">shareholders</font> may enforce  their rights to have the Put Shares purchased</td>
    </tr>
    <tr>
      <td>At this time, <font color="blue">the Company </font>does  not have an <font color="blue">alternative</font> plan to satisfy the DAW <font color="blue">Shareholders</font>, and the DAW  <font color="blue"><font color="blue">Shareholders</font> </font><font color="blue">may then seek</font> to enforce their rights in a <font color="blue">manner which would</font> be  material adverse to <font color="blue">the Company </font>and its <font color="blue">shareholders</font></td>
    </tr>
    <tr>
      <td>We Do Not Possess Depth in Our Management Team         The success of Nyer is <font color="blue">principally <font color="blue">dependent</font> upon</font> the efforts of the  President and Chief Executive Officer, Karen L Wright and the <font color="blue">management</font> team  of the pharmacies</td>
    </tr>
    <tr>
      <td>With the exception of its <font color="blue">medical products</font> <font color="blue">distribution</font>  companies, Nyer does not provide any operating support to its <font color="blue">subsidiaries</font> and  limits its <font color="blue">services principally</font> to <font color="blue">supplying <font color="blue">accounting</font> services</font> to its  <font color="blue">subsidiaries</font></td>
    </tr>
    <tr>
      <td>For this reason, Nyer has not needed the services of <font color="blue">additional</font>  <font color="blue">management</font>, beyond its <font color="blue">executive officer</font> and the minority <font color="blue">shareholders</font> of  Eaton</td>
    </tr>
    <tr>
      <td>As Nyer continues to grow, it may require the services of <font color="blue">additional</font>  <font color="blue">executives</font></td>
    </tr>
    <tr>
      <td>The loss of certain other <font color="blue">key employees could</font> have a material  effect upon the business of Nyer</td>
    </tr>
    <tr>
      <td>At the present time, Nyer has key-man  <font color="blue">insurance on</font> the lives of the minority <font color="blue">shareholders</font> and does not have any on  its <font color="blue">executive officer</font> nor does it intend to do so</td>
    </tr>
    <tr>
      <td>No assurances can be given  that Nyer can recruit suitable qualified <font color="blue">executives</font>, if <font color="blue">necessary</font></td>
    </tr>
    <tr>
      <td>Control of Nyer Is Held By a Few <font color="blue"><font color="blue">Shareholders</font> </font>        Nyerapstas <font color="blue">principal shareholder</font>, <font color="blue">Nyle International Corp</font></td>
    </tr>
    <tr>
      <td>(Nyle), a  <font color="blue">corporation</font> controlled by Mr</td>
    </tr>
    <tr>
      <td>Samuel Nyer, owns 781cmam000 shares of <font color="blue">common stock</font>  of Nyer</td>
    </tr>
    <tr>
      <td>In addition, Nyle owns 2cmam000 shares of Class A <font color="blue"><font color="blue">preferred stock</font> which</font>  has <font color="blue">voting rights</font> equal to 2cmam000cmam000 shares of <font color="blue">common stock</font> of Nyer on all  matters that come before the common <font color="blue">shareholders</font> for vote</td>
    </tr>
    <tr>
      <td>Nyer <font color="blue">personally</font>  owns 101cmam400 shares of <font color="blue">common stock</font> of Nyer and 1cmam000 shares <font color="blue">of Class B  </font><font color="blue">preferred stock</font> of Nyer which has <font color="blue">voting rights</font> equal to 2cmam000cmam000 shares of  <font color="blue">common stock</font> of Nyer on all matters that come before the common <font color="blue">shareholders</font> to  vote</td>
    </tr>
    <tr>
      <td>As a result, <font color="blue">Nyle and Mr</font></td>
    </tr>
    <tr>
      <td>Nyer <font color="blue"><font color="blue">effective</font>ly control</font> the  <font color="blue">voting power</font> of  Nyer</td>
    </tr>
    <tr>
      <td>Accordingly, <font color="blue">Nyle and Mr</font></td>
    </tr>
    <tr>
      <td>Nyer are in the position to  elect a majority of Nyerapstas <font color="blue">directors</font> and control the policies and <font color="blue">operations</font> of  Nyer</td>
    </tr>
    <tr>
      <td>Many of Our Competitors Have Advantages Over Us         All aspects of our business are subject to <font color="blue"><font color="blue">significant</font> <font color="blue">competition</font></font></td>
    </tr>
    <tr>
      <td>Many  of our <font color="blue">competitors</font> <font color="blue">generally</font> have <font color="blue">substantially</font> greater financial resources and  other <font color="blue">competitive</font> <font color="blue">advantages</font></td>
    </tr>
    <tr>
      <td>Such <font color="blue">greater resources</font> and <font color="blue">advantages</font> may reduce  our chance for <font color="blue">economic success</font></td>
    </tr>
    <tr>
      <td>Volatility in the Stock Market May Have a Negative Impact on the Price of Our  Stock         The <font color="blue">stock market</font> has from time to time experienced <font color="blue"><font color="blue">significant</font> price</font> and  <font color="blue">volume fluctuations</font> that may be unrelated to the operating performance of any  <font color="blue">particular company</font></td>
    </tr>
    <tr>
      <td>This as well as other <font color="blue">factors which</font> are directly related  to our <font color="blue">businesses</font>, could impact the <font color="blue">market price</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td><font color="blue">Further  </font>because of the small volume of trading in our <font color="blue">common stock</font>, the <font color="blue">market price</font> of  the <font color="blue">common stock</font> can be <font color="blue">affected by increases</font> in <font color="blue">trading volume</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">common stock</font> is listed on the <font color="blue">NASDAQ Stock Market LLC </font> NASDAQ rules  provide that if the <font color="blue">market price</font> of a <font color="blue">common stock</font> is less than dlra1 for thirty  <font color="blue">consecutive trading days</font>, it can be <font color="blue">delisted upon</font> the happening of certain  events</td>
    </tr>
    <tr>
      <td>If our <font color="blue">common stock</font> is <font color="blue">delisted by</font> NASDAQ, the <font color="blue">market price</font> of the  <font color="blue">common stock</font> may be <font color="blue">negatively impacted</font></td>
    </tr>
    <tr>
      <td>Risks related to ownership of our <font color="blue">common stock</font>    The exercise of our <font color="blue">outstanding stock</font> options <font color="blue">could adversely affect</font> our  outstanding <font color="blue">common stock</font>         Our <font color="blue">stock option</font> plans are an important component of our <font color="blue">compensation</font>  program for our employees, <font color="blue">directors</font> and <font color="blue">consultants</font></td>
    </tr>
    <tr>
      <td><font color="blue">As of June </font>30, 2006, we  have issued and <font color="blue">outstanding options</font> to purchase approximately 1cmam682cmam600 shares  of <font color="blue">common stock</font> withexercise prices ranging from dlra1dtta29 to dlra16dtta75 per share</td>
    </tr>
    <tr>
      <td>The existence of <font color="blue">such rights</font> to acquire <font color="blue">common stock</font> at fixed <font color="blue">prices may prove</font>  a hindrance to our efforts to <font color="blue">raise future funding by</font> the sale of equity</td>
    </tr>
    <tr>
      <td>The  exercise of <font color="blue">such options will dilute</font> the <font color="blue">percentage ownership interest</font> of our  <font color="blue">existing stockholders</font> and may dilute the value of their ownership</td>
    </tr>
    <tr>
      <td>The  <font color="blue">possible future sale</font> of <font color="blue">shares issuable on</font> the exercise of <font color="blue">outstanding options</font>  <font color="blue">could adversely affect</font> the prevailing <font color="blue">market price</font> for our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Further, the holders of the <font color="blue">outstanding rights may exercise them at</font> a time when  we <font color="blue">would otherwise</font> be able to obtain <font color="blue">additional</font> equity capital on terms more  favorable to us</td>
    </tr>
    <tr>
      <td>Investors Should Not Expect Dividends         Nyer intends to retain <font color="blue">future earnings</font>, if any, to finance its growth</td>
    </tr>
    <tr>
      <td>The Companies Which Comprise Nyer Have Not Historically Operated as a Combined  Business         The <font color="blue">subsidiaries</font> that comprise Nyer have <font color="blue">been <font color="blue">historically</font> managed</font> or  operated as individual, stand-alone <font color="blue">businesses</font></td>
    </tr>
    <tr>
      <td>Although we believe that we  have and can continue to <font color="blue">successfully manage</font> and operate these separate and  individual <font color="blue">businesses</font>, we cannot be certain of this</td>
    </tr>
    <tr>
      <td>Certain risks are inherent in <font color="blue">providing pharmacy services</font>; our <font color="blue">insurance may</font>  not be adequate to cover any claims <font color="blue">against us</font>         Our pharmacies are exposed to <font color="blue">risks inherent</font> in the packaging and  <font color="blue">distribution</font> of <font color="blue">pharmaceuticals</font> and other healthcare products, such as improper  filling of <font color="blue">prescriptions</font>, labeling of <font color="blue">prescriptions</font> and adequacy of warnings</td>
    </tr>
    <tr>
      <td>Although we maintain <font color="blue">professional liability</font> and errors and <font color="blue">omissions liability</font>  insurance, from time to time, claims result in the payment of <font color="blue">significant</font>  amounts, some portions of which are not <font color="blue">funded by insurance</font></td>
    </tr>
    <tr>
      <td>We can offer no  assurance that the <font color="blue">coverage limits under</font> our insurance programs will be  adequate to <font color="blue">protect us against future</font> claims, or that we will maintain this  <font color="blue">insurance on</font> acceptable terms in the future</td>
    </tr>
    <tr>
      <td>Our results of <font color="blue">operations</font>,  <font color="blue">financial condition</font> or <font color="blue">cash flows may adversely</font> be affected if in the future  our <font color="blue">insurance coverage proves</font> to be inadequate or unavailable or we may suffer  harm to our <font color="blue">reputation as</font> a result of an error or omission</td>
    </tr>
    <tr>
      <td>Product Liability Claims May Arise in the Future of Medical Products         The sale of <font color="blue"><font color="blue">medical products</font> entails</font> the risk that <font color="blue">users will pursue</font>  <font color="blue">product liability</font> claims</td>
    </tr>
    <tr>
      <td>Although we are a <font color="blue">distributor</font> and not a <font color="blue"><font color="blue">manufacture</font>r</font>  of <font color="blue">medical products</font> and are <font color="blue">therefore less likely</font> to be <font color="blue">ultimately liable</font> in a  <font color="blue">product liability</font> suit, a <font color="blue">product liability</font> claim could be made <font color="blue">against us</font> and  could be expensive for us</td>
    </tr>
    <tr>
      <td>Our <font color="blue">insurance may</font> not <font color="blue">provide adequate coverage</font>  against these claims</td>
    </tr>
    <tr>
      <td>Our Success May Vary With Regulation of and Changes in the Practice of Medicine         The <font color="blue"><font color="blue">health care</font> industry</font> is subject to extensive <font color="blue">government regulation</font>,  licensure and operating procedures</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot predict</font> the impact that present  or <font color="blue">future <font color="blue">regulations</font> may</font> have on <font color="blue">operations</font> of Eaton and ADCO  Eatonapstas  <font color="blue"><font color="blue">pharmacists</font> also may</font> have a duty to <font color="blue">warn customers</font> regarding <font color="blue">potential negative</font>  effects of a <font color="blue">prescription drug</font> if the <font color="blue">warning could reduce</font> or negate these  effects</td>
    </tr>
    <tr>
      <td>Additionally, Eaton is subject to federal <font color="blue">Drug Enforcement Agency </font>and  state <font color="blue">regulations</font> relating to pharmacy <font color="blue">operations</font>,purchasing, storing and  dispensing of controlled substances</td>
    </tr>
    <tr>
      <td>Eaton is also subject to other federal  <font color="blue">regulations</font> such as The Health Insurance Portability and Accountability  Act of 1996 (HIPAA)</td>
    </tr>
    <tr>
      <td>Moreover, <font color="blue">as consolidation among physician provider</font>  groups, long-term care facilities and other alternate-site providers continues  and <font color="blue">provider networks</font> are created, <font color="blue">purchasing decisions may</font> shift to  <font color="blue">individuals with whom</font> Eaton and ADCO have not had <font color="blue">prior selling <font color="blue">relationship</font>s</font></td>
    </tr>
    <tr>
      <td>There can be no assurance that Eaton and ADCO will be able to maintain its  <font color="blue">customer <font color="blue">relationship</font>s</font> in <font color="blue">such circumstances</font> or that <font color="blue">such provider</font>  <font color="blue">consolidation will</font> not result in reduced operating margins</td>
    </tr>
    <tr>
      <td>Also, national  <font color="blue"><font color="blue">health care</font> reform</font> has been the subject of a number of <font color="blue">legislative <font color="blue">initiatives</font></font>  by Congress</td>
    </tr>
    <tr>
      <td>Due to <font color="blue">uncertainties</font> regarding the ultimate features of health  care reform <font color="blue">initiatives</font> and their <font color="blue">enactment</font> and <font color="blue">implementation</font>, Eaton and ADCO  <font color="blue">cannot predict</font> which, if any, of <font color="blue">such <font color="blue">reform proposals</font> will</font> be adopted, when  they may be adopted or what impact they may have on Eaton and ADCO or their  customers</td>
    </tr>
    <tr>
      <td>The <font color="blue">actual announcement</font> of <font color="blue">reform proposals</font> and the investment  communityapstas reaction to such proposals, announcements by <font color="blue">competitors</font> of their  strategies to respond to reform <font color="blue">initiatives</font> and <font color="blue">general industry conditions</font>  could produce <font color="blue">volatility</font> in the trading and <font color="blue">market price</font> of Nyer <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Pricing Pressures From Health Care Providers and Third-Party Payors Exists for  Us         The cost of a <font color="blue">significant</font> portion of <font color="blue">medical care</font> in the <font color="blue">United States </font>is  <font color="blue">funded by government</font> and private insurance programs, such as Medicare, Medicaid  and corporate health insurance plans</td>
    </tr>
    <tr>
      <td>In recent years, government-imposed  <font color="blue">limits on <font color="blue">reimbursement</font></font> of hospitals and other <font color="blue"><font color="blue">health care</font> providers</font> have  <font color="blue">significant</font>ly impacted spending budgets in <font color="blue">certain markets within</font> the medical  <font color="blue">products industry</font></td>
    </tr>
    <tr>
      <td>Private third-party <font color="blue">reimbursement</font> plans are also developing  <font color="blue">increasingly sophisticated methods</font> of <font color="blue">controlling <font color="blue">health care</font> costs through</font>  redesign of benefits and <font color="blue">exploration</font> of more cost-<font color="blue">effective</font> methods of  delivering <font color="blue">health care</font></td>
    </tr>
    <tr>
      <td>Accordingly, there can be no assurance that  <font color="blue">reimbursement</font> for purchase and use of <font color="blue">medical products</font> will not be limited or  reduced and <font color="blue">thereby adversely affect future sales by</font> Eaton and ADCO  In  addition, any substantial delays in <font color="blue">reimbursement</font>, <font color="blue">significant</font> reduction in  coverage or <font color="blue">payment rates from <font color="blue">third party</font> payors</font> can have a material adverse  effect on our <font color="blue">retail pharmacy</font> business</td>
    </tr>
    <tr>
      <td>Pharmacy sales to <font color="blue">third party</font> plans  accounted for 90prca of our <font color="blue">total pharmacy sales</font> for the <font color="blue">fiscal year</font> ended 2006,  81prca for the <font color="blue">fiscal year</font> ended 2005 and 83prca for the <font color="blue">fiscal year</font> ended 2004</td>
    </tr>
    <tr>
      <td>Eaton is <font color="blue">Dependent </font>on <font color="blue">Relationships </font>with Vendors         Eaton is <font color="blue"><font color="blue"><font color="blue">dependent</font> on</font> vendors</font> to <font color="blue">manufacture</font> and <font color="blue">supply products</font></td>
    </tr>
    <tr>
      <td>During  the 12-month period ended June 30, 2006, Eaton had <font color="blue">one vendor whose</font>  <font color="blue">relationship</font>  <font color="blue">accounts</font> for 88dtta2prca of their <font color="blue">inventory purchases</font></td>
    </tr>
    <tr>
      <td>We believe if <font color="blue">necessary</font>, we  can replace the <font color="blue">vendor with no adverse cost</font> effect</td>
    </tr>
    <tr>
      <td>Eatonapstas ability to maintain good <font color="blue"><font color="blue">relations with</font> <font color="blue">vendors will affect</font></font> the  <font color="blue">profitability</font> of its business</td>
    </tr>
    <tr>
      <td>Currently, Eaton <font color="blue">relies on</font> its vendors to  provide: (i) agreeable purchasing and delivery terms; (ii) sales performance  incentives; (iii) financial support of sales and <font color="blue">marketing programs</font>; and (iv)  <font color="blue">promotional materials</font></td>
    </tr>
    <tr>
      <td>There can be no assurance that Eaton will maintain good  <font color="blue">relations with</font> its vendors</td>
    </tr>
    <tr>
      <td>Eaton is <font color="blue">Dependent </font>on Employees         Eaton <font color="blue">depends on</font> the <font color="blue">continued service</font> of, and on the ability to attract,  motivate and retain, a sufficient number of <font color="blue">pharmacists</font> for our stores</td>
    </tr>
    <tr>
      <td>We  believe that our <font color="blue">success depends</font> in part on our <font color="blue">continued ability</font> to attract  and retain qualified and skilled <font color="blue">pharmacists</font></td>
    </tr>
    <tr>
      <td>Over the years, a <font color="blue">significant</font>  shortage of <font color="blue">pharmacists</font> has developed due to industry <font color="blue">competition</font> as well as  <font color="blue">competition</font> from other <font color="blue">industries</font></td>
    </tr>
    <tr>
      <td>This has resulted in <font color="blue">continued upward</font>  pressure on pharmacist <font color="blue">compensation</font> packages</td>
    </tr>
    <tr>
      <td>There can be no assurance that  we will be able to attract, hire and retain <font color="blue">sufficient numbers</font> of <font color="blue">pharmacists</font>  <font color="blue">necessary</font> to continue to develop and grow our business</td>
    </tr>
    <tr>
      <td>The <font color="blue">inability</font> to  attract and retain a sufficient number of <font color="blue">pharmacists</font> could limit our ability  to <font color="blue">increase revenue</font> and impact our ability to deliver <font color="blue">high levels</font> of customer  care</td>
    </tr>
    <tr>
      <td>ADCO Is <font color="blue">Dependent </font>on <font color="blue">Relationships </font>with Vendors         ADCO <font color="blue">distributes from</font> its stock over 4cmam000 <font color="blue">medical products</font> <font color="blue">manufacture</font>d  by approximately 135 vendors and is <font color="blue"><font color="blue">dependent</font> on</font> these vendors for the  <font color="blue">manufacture</font> and supply of products</td>
    </tr>
    <tr>
      <td>During the 12-month period ended June 30,  2006, ADCO had one vendor, a buying group, whose <font color="blue">relationship</font> accounted for 20prca  of ADCOapstas <font color="blue">inventory purchases</font></td>
    </tr>
    <tr>
      <td>If the <font color="blue">relationship</font> with this buying group was  disrupted, <font color="blue">management</font> believes it has at least two <font color="blue">competitive</font> buying groups  who could fulfill their inventory needs but it may be at <font color="blue">additional</font> expense</td>
    </tr>
    <tr>
      <td>ADCOapstas ability to maintain good <font color="blue">relations with</font> these <font color="blue">vendors will affect</font>  the <font color="blue">profitability</font> of its business</td>
    </tr>
    <tr>
      <td>Currently, ADCO <font color="blue">relies on</font> vendors to  provide: (i) field <font color="blue">sales <font color="blue">representative</font></font>s &amp;apos  technical and selling support; (ii)  agreeable purchasing and  delivery terms; (iii) sales performance incentives;  (iv) financial support of sales and <font color="blue">marketing programs</font>; and (v) promotional  materials</td>
    </tr>
    <tr>
      <td>The Success of ADCO Is <font color="blue">Dependent </font>on Qualified Sales Representatives         ADCO believes that to be successful it <font color="blue">must continue</font> to hire, train and  retain <font color="blue">highly qualified <font color="blue">sales <font color="blue">representative</font></font>s</font></td>
    </tr>
    <tr>
      <td>Due to the <font color="blue">relationship</font>s  developed between ADCOapstas <font color="blue">sales <font color="blue">representative</font></font>s and its customers, upon the  <font color="blue">departure</font> of a <font color="blue">sales <font color="blue">representative</font></font>, ADCO faces the risk of losing the  <font color="blue">representative</font>apstas customers, especially if the <font color="blue">representative</font> were to act as a  <font color="blue">representative</font> of ADCOapstas <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>ADCO <font color="blue">generally</font> requires its sales  <font color="blue">representative</font>s to execute a non-<font color="blue">competition</font> <font color="blue">agreement</font> as a condition of their  <font color="blue">employment</font></td>
    </tr>
    <tr>
      <td>Although courts have <font color="blue">generally</font> upheld the terms of non-<font color="blue">competition</font>  <font color="blue">agreement</font>s similar to ADCOapstas in the past, there can be no assurance that such  <font color="blue">agreement</font>s will be upheld in the future</td>
    </tr>
    <tr>
      <td><font color="blue">ADCO Relies </font>on Third-Party Shippers         Because ADCO believes that its success to date is <font color="blue">dependent</font> in part upon  its ability to <font color="blue">provide prompt</font>, accurate and complete service to its customers  on a price-<font color="blue">competitive</font> basis, any material increases in its costs of procuring  and delivering <font color="blue">products could</font> have an adverse effect on its results of  <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Strikes or other <font color="blue">service interruptions affecting</font> United Parcel  Service or other <font color="blue">common carriers used by</font> ADCO to ship its <font color="blue">products could</font> impair  ADCOapstas ability to deliver <font color="blue">products on</font> a timely and cost-<font color="blue">effective</font> basis</td>
    </tr>
    <tr>
      <td>In  addition, because ADCO <font color="blue">typically bears</font> the cost of shipment to its customers,  any increase in <font color="blue">shipping rates could</font> have an adverse effect on ADCOapstas operating  results</td>
    </tr>
    <tr>
      <td><font color="blue">Compliance </font>with changing regulation of <font color="blue">corporate governance</font> and public  <font color="blue"><font color="blue">disclosure</font> may</font> result in <font color="blue">additional</font> expenses         <font color="blue">Changing </font>laws, <font color="blue">regulations</font> and standards relating to <font color="blue">corporate governance</font>  and <font color="blue">public <font color="blue">disclosure</font></font>, including the Sarbanes-Oxley Act of 2002, new Securities  and Exchange Commission, or SEC, <font color="blue">regulations</font> and <font color="blue">NASDAQ Stock Market LLC </font>rules,  are creating <font color="blue">uncertainty</font> for <font color="blue">companies such as ours</font></td>
    </tr>
    <tr>
      <td>These new or changed  laws, <font color="blue">regulations</font> and standards are subject to <font color="blue">varying interpretations</font> in many  <font color="blue">cases due</font> to their lack of <font color="blue">specificity</font>, and as a result, their <font color="blue">application</font> in  <font color="blue">practice may evolve over</font> time <font color="blue">as new guidance</font> is <font color="blue">provided by regulatory</font> and  governing bodies, which could result in continuing <font color="blue">uncertainty</font> regarding  <font color="blue">compliance matters</font> and <font color="blue">higher costs necessitated by ongoing revisions</font> to  <font color="blue">disclosure</font> and <font color="blue">governance practices</font></td>
    </tr>
    <tr>
      <td>As a result, our efforts to <font color="blue">comply with</font>  evolving laws, <font color="blue">regulations</font> and standards have resulted in, and are likely to  continue to result in, <font color="blue">increased general</font> and <font color="blue">administrative expenses</font> and a  diversion of <font color="blue">management</font> time and attention from revenue-generating <font color="blue">activities</font>  to <font color="blue">compliance <font color="blue">activities</font></font></td>
    </tr>
    <tr>
      <td>In particular, our <font color="blue">ongoing efforts</font> to <font color="blue">comply with</font>  Section 404 of the Sarbanes-Oxley Act of 2002 and the related <font color="blue">regulations</font>  regarding our <font color="blue">management</font>apstas required <font color="blue">assessment</font> of our <font color="blue">internal control over</font>  financial reporting and our in<font color="blue">dependent</font> registered public <font color="blue">accounting</font> firmapstas  <font color="blue">attestation</font> of that <font color="blue">assessment</font> will require the <font color="blue">commitment</font> of financial and  <font color="blue">managerial resources</font></td>
    </tr>
    <tr>
      <td>We expect these efforts to require the continued  <font color="blue">commitment</font> of resources</td>
    </tr>
    <tr>
      <td>In addition, Executive Compensation and Related  Party Disclosure, <font color="blue">which will soon</font> be required of us, will also require  <font color="blue">commitment</font> of financial and <font color="blue">managerial resources</font></td>
    </tr>
    <tr>
      <td>If our efforts to comply  with new or changed laws, <font color="blue">regulations</font> and <font color="blue">standards differ from</font> the <font color="blue">activities</font>  <font color="blue">intended by regulatory</font> or <font color="blue">governing bodies due</font> to <font color="blue">ambiguities</font> related to  practice, our <font color="blue">reputation may</font> be harmed</td>
    </tr>
    <tr>
      <td>While we believe that we currently have adequate <font color="blue">internal control over</font>  financial reporting, we are exposed to <font color="blue">risks from legislation</font> requiring  companies to evaluate those <font color="blue">internal controls</font></td>
    </tr>
    <tr>
      <td>Section 404 of the Sarbanes-Oxley Act of 2004 requires our <font color="blue">management</font> to  report on, and our in<font color="blue">dependent</font> registered public <font color="blue">accounting</font> firm to attest to,  the <font color="blue"><font color="blue">effective</font>ness</font> of our internal control structure and procedures for  financial reporting</td>
    </tr>
    <tr>
      <td>Under the new compliance schedule, we will be required to  <font color="blue">comply with</font> <font color="blue">the Section </font>404 <font color="blue">requirements</font> for our <font color="blue">fiscal year</font> ending on June 30,  2008</td>
    </tr>
    <tr>
      <td>In the event that our chief <font color="blue">executive officer</font> or in<font color="blue">dependent</font> registered  public <font color="blue">accounting</font> firm determines that our <font color="blue">internal control over</font> financial  reporting is not <font color="blue">effective</font> as defined under Section 404, investor perceptions  and the reputation of our <font color="blue">company may</font> be <font color="blue">adversely affected</font> and could cause a  decline in the <font color="blue">market price</font> of our stock</td>
    </tr>
    <tr>
      <td>We are subject to <font color="blue">additional</font> rules and <font color="blue">regulations</font> as a <font color="blue">public company</font>,  <font color="blue">which will increase</font> our <font color="blue">administration costs which</font> in turn <font color="blue">could harm</font> our  operating results</td>
    </tr>
    <tr>
      <td>As a <font color="blue">public company</font>, we incur <font color="blue">significant</font> legal, <font color="blue">accounting</font> and other  expenses</td>
    </tr>
    <tr>
      <td>In addition, the Sarbanes-Oxley Act of 2002, as well as new rules  <font color="blue">subsequently</font> implemented by the SEC, have required changes in corporate  <font color="blue">governance practices</font> of <font color="blue">public companies</font></td>
    </tr>
    <tr>
      <td>n addition to <font color="blue">final rules</font> and rule  <font color="blue">proposals already</font> made by the SEC, NASDAQ <font color="blue">adopted revisions</font> to its  <font color="blue">requirements</font> for companies that are NASDAQ-listed</td>
    </tr>
    <tr>
      <td>These rules and  <font color="blue">regulations</font> have increased our legal and <font color="blue">financial compliance costs</font>, and made  some <font color="blue">activities</font> more time consuming or costly</td>
    </tr>
    <tr>
      <td>We also expect these rules and  <font color="blue">regulations</font> to make it more <font color="blue">difficult</font> and more expensive for us to obtain  director and <font color="blue">officer liability insurance</font>, and we may be required to accept  <font color="blue">reduced coverage</font> or incur <font color="blue">substantially</font> higher costs to obtain coverage</td>
    </tr>
    <tr>
      <td>These  rules and <font color="blue">regulations</font> could also make it more <font color="blue">difficult</font> for us to attract and  retain <font color="blue">qualified members</font> of our board of <font color="blue">directors</font>, particularly to serve on  our <font color="blue">audit committee</font>, and qualified <font color="blue">executive officer</font>s</td>
    </tr>
    <tr>
      <td>Changes to financial <font color="blue">accounting</font> standards may affect our results of <font color="blue">operations</font>  and cause us to change our business practices</td>
    </tr>
    <tr>
      <td>We prepare our <font color="blue">financial statements</font> to conform to <font color="blue">generally</font> accepted  <font color="blue">accounting</font> principles, or GAAP  These <font color="blue">accounting</font> principles are subject to  interpretation by the Public Company Accounting Oversight Board, Financial  Accounting Standards Board, American Institute of Certified Public Accountants,  the SEC and various bodies formed to interpret and create <font color="blue">appropriate</font>  <font color="blue">accounting</font> policies</td>
    </tr>
    <tr>
      <td>A change in those policies can have a <font color="blue">significant</font> effect  on our reported results and may affect our reporting of <font color="blue">transaction</font>s completed  before a change is announced</td>
    </tr>
    <tr>
      <td>Changes to those rules or the questioning of  <font color="blue">current practices may adversely affect</font> our reported financial results or the  way we conduct our business</td>
    </tr>
    <tr>
      <td>For example, <font color="blue">accounting</font> policies affecting many  aspects of our business, including rules relating to employee <font color="blue">stock option</font>  grants, have <font color="blue">recently been revised</font></td>
    </tr>
    <tr>
      <td>The FASB and other <font color="blue">agencies finalized</font>  changes to GAAP that required us, in our quarter ending <font color="blue">September </font>30, 2005, to  record a charge to earnings for employee <font color="blue">stock option</font> grants</td>
    </tr>
    <tr>
      <td>We may have  <font color="blue">significant</font> and ongoing <font color="blue">accounting</font> charges resulting <font color="blue">from option grant</font> that we  expect will reduce our <font color="blue">overall net income</font></td>
    </tr>
    <tr>
      <td>In addition, since we <font color="blue">historically</font>  have used equity-related <font color="blue">compensation</font> as a component of our <font color="blue">total employee</font>  <font color="blue">compensation</font> program, the <font color="blue">accounting</font> change could make the use of  equity-related <font color="blue">compensation</font> less attractive to us and therefore make it more  <font color="blue">difficult</font> to attract and retain employees and <font color="blue">directors</font></td>
    </tr>
  </tbody>
</table>